Search

Find exactly what you’re looking for.

Showing 21-40 of 112 results

Welcome to the first edition of Saul Ewing’s Public Companies Quarterly Update series. Our intent is to, on a quarterly basis, highlight important legal developments of which we think public companies should be aware. This first edition is related to developments during the first quarter of 2023. If...

In February, 2023, the Antitrust Division of the Department of Justice (“DOJ”) announced they are withdrawing three (3) antitrust policy statements – two of which date from the 1990s – which have been relied upon by healthcare providers and their counsel guiding them through their merger and...

This checklist highlights certain considerations for companies preparing to file annual reports on Form 10-K for calendar year 2022. This list is not intended to be exhaustive and is not a substitute for your understanding of the requirements. It is simply a checklist of items that are new to this...

BACKGROUND: The Rule - What It Means and What It Prohibits A somewhat little-known and obscure provision of U.S. antitrust law – Section 8 of the Clayton Act – makes it illegal in certain circumstances for the same person to serve as a director of competing corporations. If certain conditions exist...

LATEST UPDATE The FTC has voted to extend the public comment period on its proposed rule to ban employers from imposing non-competes on their workers, and will now be accepting comments on the proposed rule until April 19, 2023. Comments can still be submitted in either writing or online using the...

The use of artificial intelligence (AI) to create works of art and inventions raises interesting legal challenges to the protection of intellectual property (IP). The plain language of the Copyright Act and Patent Act present obstacles to inventors and artists who may use or be AI systems. Recent...

Saul Ewing LLP represented Genesis Unicorn Capital, LLC, in its acquisition of and role as the sole sponsor for Genesis Unicorn Capital Corp. a special purpose acquisition company (SPAC), in the SPAC's $75 Million initial public offering (IPO) of 7,500,000 units at a price of $10.00 per unit. The...

Saul Ewing LLP represented Signal Hill Acquisition Corp., a special purpose acquisition company, in its initial public offering of 10,000,000 units at a price of $10.00 per unit, resulting in gross proceeds of $100,000,000. The units are listed on The Nasdaq Global Market (Nasdaq) and began trading...

Veronica McCarty is a litigator who represents inventors and companies in intellectual property disputes, particularly for inventions involving computing and biopharmaceutical technologies, as well as medical devices. Veronica works on patent trials, including on ANDA bench trials, and she assists...

Industry-Specific, Business-Focused Legal Advice Increased pricing pressure combined with a rise in generic competition and continued regulatory uncertainty have squeezed the margins of life sciences companies. Helping navigate this ever-shifting terrain, Saul Ewing’s Life Sciences Practice consists...

George "Ned" Rahn focuses his practice on commercial litigation including national and international construction matters. He has handled matters for contractors, engineering firms, owners, and surety bond companies in a variety of contexts. Ned has dealt with matters for general contractors...

Eric Orlinsky co-chairs the firm's Corporate Practice and its Private Equity/Venture Capital subgroup and concentrates his practice in general business and securities law and counsels clients in private equity and venture capital investments, public and private offerings of debt and equity...

Charlie Monk handles complex, high-stakes litigation. During his 40 years as a trial lawyer, clients ranging from governmental entities and security broker dealers to energy providers and utilities have relied on his legal counsel to help them deal with complex litigation. He has led teams dealing...

Charlie Lizza brings more than 40 years of litigation experience to his representation of pharmaceutical companies in high stakes patent litigation. Mr. Lizza concentrates his practice in Hatch-Waxman ANDA litigation and protecting the intellectual property of branded pharmaceutical and medical...

For More Information